233 related articles for article (PubMed ID: 16386391)
21. Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery.
Díez S; Tros de Ilarduya C
Eur J Pharm Biopharm; 2006 Jun; 63(2):188-97. PubMed ID: 16697172
[TBL] [Abstract][Full Text] [Related]
22. Quantitative three-dimensional analysis of poly (lactic-co-glycolic acid) microsphere using hard X-ray nano-tomography revealed correlation between structural parameters and drug burst release.
Huang X; Li N; Wang D; Luo Y; Wu Z; Guo Z; Jin Q; Liu Z; Huang Y; Zhang Y; Wu C
J Pharm Biomed Anal; 2015 Aug; 112():43-9. PubMed ID: 25951620
[TBL] [Abstract][Full Text] [Related]
23. Simple and scalable method for peptide inhalable powder production.
Schoubben A; Blasi P; Giovagnoli S; Ricci M; Rossi C
Eur J Pharm Sci; 2010 Jan; 39(1-3):53-8. PubMed ID: 19879945
[TBL] [Abstract][Full Text] [Related]
24. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
Zhao A; Rodgers VG
J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
[TBL] [Abstract][Full Text] [Related]
25. Through-thickness plasma modification of biodegradable and nonbiodegradable porous polymer constructs.
Safinia L; Wilson K; Mantalaris A; Bismarck A
J Biomed Mater Res A; 2008 Dec; 87(3):632-42. PubMed ID: 18189299
[TBL] [Abstract][Full Text] [Related]
26. Monodisperse polymeric particles prepared by ink-jet printing: double emulsions, hydrogels and polymer mixtures.
Böhmer MR; Steenbakkers JA; Chlon C
Colloids Surf B Biointerfaces; 2010 Aug; 79(1):47-52. PubMed ID: 20413282
[TBL] [Abstract][Full Text] [Related]
27. Thermal behavior and stability of biodegradable spray-dried microparticles containing triamcinolone.
da Silva AA; de Matos JR; Formariz TP; Rossanezi G; Scarpa MV; do Egito ES; de Oliveira AG
Int J Pharm; 2009 Feb; 368(1-2):45-55. PubMed ID: 18992313
[TBL] [Abstract][Full Text] [Related]
28. Fabrication of multi-layered biodegradable drug delivery device based on micro-structuring of PLGA polymers.
Ryu WH; Vyakarnam M; Greco RS; Prinz FB; Fasching RJ
Biomed Microdevices; 2007 Dec; 9(6):845-53. PubMed ID: 17577671
[TBL] [Abstract][Full Text] [Related]
29. Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography.
Straub JA; Chickering DE; Church CC; Shah B; Hanlon T; Bernstein H
J Control Release; 2005 Nov; 108(1):21-32. PubMed ID: 16126299
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification.
Gasparini G; Kosvintsev SR; Stillwell MT; Holdich RG
Colloids Surf B Biointerfaces; 2008 Feb; 61(2):199-207. PubMed ID: 17919891
[TBL] [Abstract][Full Text] [Related]
31. Injectable poly(lactic-co-glycolic) acid scaffolds with in situ pore formation for tissue engineering.
Krebs MD; Sutter KA; Lin AS; Guldberg RE; Alsberg E
Acta Biomater; 2009 Oct; 5(8):2847-59. PubMed ID: 19446056
[TBL] [Abstract][Full Text] [Related]
32. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
33. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
34. Fabrication and characterization of permeable degradable poly(DL-lactide-co-glycolide) (PLGA) hollow fiber phase inversion membranes for use as nerve tract guidance channels.
Wen X; Tresco PA
Biomaterials; 2006 Jul; 27(20):3800-9. PubMed ID: 16564567
[TBL] [Abstract][Full Text] [Related]
35. The production of uniformly sized polymer microspheres.
Amsden B
Pharm Res; 1999 Jul; 16(7):1140-3. PubMed ID: 10450945
[No Abstract] [Full Text] [Related]
36. Sterilization of gentamicin containing collagen/PLGA microparticle composites.
Friess W; Schlapp M
Eur J Pharm Biopharm; 2006 Jun; 63(2):176-87. PubMed ID: 16497493
[TBL] [Abstract][Full Text] [Related]
37. Production and characterization of anisotropic particles from biodegradable materials.
Romanski FS; Winkler JS; Riccobene RC; Tomassone MS
Langmuir; 2012 Feb; 28(8):3756-65. PubMed ID: 22283562
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the influence of the addition of biodegradable polymer matrices in the formulation of self-curing polymer systems for biomedical purposes.
Franco-Marquès E; Méndez JA; Gironès J; Ginebra MP; Pèlach MA
Acta Biomater; 2009 Oct; 5(8):2953-62. PubMed ID: 19435615
[TBL] [Abstract][Full Text] [Related]
39. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
[TBL] [Abstract][Full Text] [Related]
40. Effect of drug type on the degradation rate of PLGA matrices.
Siegel SJ; Kahn JB; Metzger K; Winey KI; Werner K; Dan N
Eur J Pharm Biopharm; 2006 Nov; 64(3):287-93. PubMed ID: 16949804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
